Your LeetCode profile is more than just a list of solved problems. It’s a story about your coding journey, your ...
Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.
Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 Inhibitor REC-4881 as Monotherapy (FAP): Updated Safety and Efficacy Najat Khan, Ph.D ., Chief R&D and Chief Commercial Officer and incoming CEO and ...
Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present ...
Scientists have mapped the atomic interactions that make nanoscale catalysts so effective at converting propane into propylene. The discovery highlights a stabilizing oxide pattern that could guide ...
Blending ‘old-fashioned’ logic systems with the neural networks that power large language models is one of the hottest trends ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback